Publications

Publications from OUS - The Lipid Clinic

379 publications found

Publications 2019

  1. Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sanchez-Hernández RM, Santos RD (2019)
    Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
    Adv Ther, 36 (7), 1786-1811
    DOI 10.1007/s12325-019-00985-8, PubMed 31102204
  2. Bogsrud MP, Græsdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, Mundal LJ, Retterstøl K, Wium C, Holven KB (2019)
    LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
    J Clin Lipidol, 13 (2), 279-286
    DOI 10.1016/j.jacl.2019.01.010, PubMed 30910667
  3. Christensen JJ, Bakke SS, Ulven SM, Retterstøl K, Henriksen T, Bollerslev J, Espevik T, Aukrust P, Halvorsen B, Holven KB (2019)
    Serum Omega-6 Fatty Acids and Immunology-Related Gene Expression in Peripheral Blood Mononuclear Cells: A Cross-Sectional Analysis in Healthy Children
    Mol Nutr Food Res, 63 (7), e1800990
    DOI 10.1002/mnfr.201800990, PubMed 30702198
  4. Holven KB, Ulven SM, Bogsrud MP (2019)
    Editorial Comment: Hyperlipidaemia and cardiovascular disease and impact of early cholesterol accumulation
    Curr Opin Lipidol, 30 (6), 490-493
    DOI 10.1097/MOL.0000000000000646, PubMed 31688171
  5. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ (2019)
    Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
    J Am Coll Cardiol, 74 (17), 2132-2146
    DOI 10.1016/j.jacc.2019.08.1024, PubMed 31648705
  6. Macpherson ME, Halvorsen B, Yndestad A, Ueland T, Mollnes TE, Berge RK, Rashidi A, Otterdal K, Gregersen I, Kong XY, Holven KB, Aukrust P, Fevang B, Jørgensen SF (2019)
    Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency
    Sci Rep, 9 (1), 9427
    DOI 10.1038/s41598-019-45861-1, PubMed 31263122
  7. Mundal LJ, Hovland A, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K (2019)
    Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia
    JAMA Cardiol (in press)
    DOI 10.1001/jamacardio.2019.3903, PubMed 31617858
  8. Müller-Wieland D, Rader DJ, Moriarty PM, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM (2019)
    Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
    J Clin Endocrinol Metab, 104 (11), 5253-5262
    DOI 10.1210/jc.2018-02703, PubMed 31166599
  9. Narverud I, Bogsrud MP, Øyri LKL, Ulven SM, Retterstøl K, Ueland T, Mulder M, Roeters van Lennep J, Halvorsen B, Aukrust P, Veierød MB, Holven KB (2019)
    Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia
    Br J Nutr, 122 (7), PII S0007114519001600-799
    DOI 10.1017/S0007114519001600, PubMed 31262370
  10. Narverud I, Christensen JJ, Bakke SS, Ulven SM, Rundblad A, Aukrust P, Espevik T, Bogsrud MP, Retterstøl K, Ueland T, Halvorsen B, Holven KB (2019)
    Profiling of immune-related gene expression in children with familial hypercholesterolaemia
    J Intern Med (in press)
    DOI 10.1111/joim.13001, PubMed 31631426
  11. Svendsen K, Jacobs DR, Røyseth IT, Garstad KW, Byfuglien MG, Granlund L, Mørch-Reiersen LT, Telle-Hansen VH, Retterstøl K (2019)
    Community pharmacies offer a potential high-yield and convenient arena for total cholesterol and CVD risk screening
    Eur J Public Health, 29 (1), 17-23
    DOI 10.1093/eurpub/cky190, PubMed 30239673
  12. Ulven SM, Holven KB, Gil A, Rangel-Huerta OD (2019)
    Milk and Dairy Product Consumption and Inflammatory Biomarkers: An Updated Systematic Review of Randomized Clinical Trials
    Adv Nutr, 10 (suppl_2), S239-S250
    DOI 10.1093/advances/nmy072, PubMed 31089732
  13. Wisløff T, Mundal LJ, Retterstøl K, Igland J, Kristiansen IS (2019)
    Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects
    Atherosclerosis, 287, 140-146
    DOI 10.1016/j.atherosclerosis.2019.06.900, PubMed 31280039
  14. Øyri LKL, Bogsrud MP, Kristiansen AL, Myhre JB, Retterstøl K, Brekke HK, Gundersen TE, Andersen LF, Holven KB (2019)
    Infant cholesterol and glycated haemoglobin concentrations vary widely-Associations with breastfeeding, infant diet and maternal biomarkers
    Acta Paediatr
    DOI 10.1111/apa.14936, PubMed 31299108
  15. Øyri LKL, Narverud I, Bogsrud MP, Hansson P, Leder L, Byfuglien MG, Veierød MB, Thoresen M, Ulven SM, Holven KB (2019)
    Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n-6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial
    J Nutr Sci, 8, e27
    DOI 10.1017/jns.2019.25, PubMed 31448116

Publications 2018

  1. Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
    Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
    J Clin Lipidol, 13 (1), 138-147
    DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415
  2. Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR (2018)
    Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
    Atherosclerosis, 278, 307-314
    DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878
  3. Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A (2018)
    Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
    J Clin Lipidol, 12 (5), 1199-1207
    DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065
  4. Holven KB, Narverud I, van Lennep JR, Versmissen J, Øyri LKL, Galema-Boers A, Langslet G, Ulven SM, Veierød MB, Retterstøl K, Bogsrud MP (2018)
    Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
    J Clin Lipidol, 12 (3), 748-755.e2
    DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857
  5. Hope S, Nordstrom M, Retterstol K, Iversen PO, Kolset SO (2018)
    The right to a health promoting diet for people with intellectual disabilities
    Tidsskr. Nor. Laegeforen., 138 (2), 122-123
  6. Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
    Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
    J Clin Lipidol, 12 (6), 1463-1470
    DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210
  7. Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K (2018)
    Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia
    Stroke, 50 (1), 172-174
    DOI 10.1161/STROKEAHA.118.023456, PubMed 30580708
  8. Kolset SO, Nordstrøm M, Hope S, Retterstøl K, Iversen PO (2018)
    Securing rights and nutritional health for persons with intellectual disabilities - a pressing challenge
    Food Nutr Res, 62
    DOI 10.29219/fnr.v62.1268, PubMed 29899685
  9. Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T (2018)
    Are PCSK9 Inhibitors Cost Effective?
    Pharmacoeconomics, 36 (9), 1031-1041
    DOI 10.1007/s40273-018-0671-0, PubMed 29777433
  10. Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA (2018)
    Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)"
    Circulation, 137 (6), 641-642
    DOI 10.1161/CIRCULATIONAHA.117.031676, PubMed 29431667
  11. Langslet G, Bogsrud MP, Wium C, Johansen D, Svilaas A, Holven KB (2018)
    Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels
    J Clin Lipidol, 12 (5), 1327-1328
    DOI 10.1016/j.jacl.2018.06.012, PubMed 30033003
  12. McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH (2018)
    Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
    Am J Cardiol, 121 (8), 940-948
    DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008
  13. Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K (2018)
    Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
    Heart, 104 (19), 1600-1607
    DOI 10.1136/heartjnl-2017-312706, PubMed 29622598
  14. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Author's response to: letter to the editor
    Heart Fail Rev, 23 (5), 819
    DOI 10.1007/s10741-018-9728-6, PubMed 30043131
  15. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
    Heart Fail Rev, 23 (3), 303-323
    DOI 10.1007/s10741-018-9685-0, PubMed 29516230
  16. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
    Response to the editor
    Heart Fail Rev (in press)
    DOI 10.1007/s10741-018-9723-y, PubMed 29968222
  17. Retterstøl K, Svendsen M, Narverud I, Holven KB (2018)
    Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study
    Atherosclerosis, 279, 52-61
    DOI 10.1016/j.atherosclerosis.2018.10.013, PubMed 30408717
  18. Svendsen K, Henriksen HB, Østengen B, Jacobs DR, Telle-Hansen VH, Carlsen MH, Retterstøl K (2018)
    Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors
    Food Nutr Res, 62
    DOI 10.29219/fnr.v62.1370, PubMed 29720928
  19. Svendsen K, Telle-Hansen VH, Mørch-Reiersen LT, Garstad KW, Thyholt K, Granlund L, Henriksen HB, Gran JM, Jacobs DR, Retterstøl K (2018)
    A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk
    Prev Med Rep, 12, 79-86
    DOI 10.1016/j.pmedr.2018.08.004, PubMed 30191097
  20. Urke EB, Søbye S, Ellingvåg A, Langslet G, Retterstøl K, Wandel M (2018)
    Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
    Patient Educ Couns, 102 (5), 1005-1012
    DOI 10.1016/j.pec.2018.12.025, PubMed 30606641

Publications 2017

  1. Berild A, Holven KB, Ulven SM (2017)
    Recommended Nordic diet and risk markers for cardiovascular disease
    Tidsskr Nor Laegeforen, 137 (10), 721-726
    DOI 10.4045/tidsskr.16.0243, PubMed 28551971
  2. Bogsrud MP, Græsdal A, Retterstøl K, Holven KB (2017)
    A physically fit woman in her thirties with exertional dyspnoea
    Tidsskr Nor Laegeforen, 137 (6), 456-458
    DOI 10.4045/tidsskr.16.0538, PubMed 28332800
  3. Bogsrud MP, Langslet G, Wium C, Johansen D, Svilaas A, Holven KB (2017)
    Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway
    J Clin Lipidol, 12 (2), 375-382
    DOI 10.1016/j.jacl.2017.11.009, PubMed 29310990
  4. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA (2017)
    Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)
    Circulation, 136 (4), 359-366
    DOI 10.1161/CIRCULATIONAHA.116.025158, PubMed 28592434
  5. Christensen JJ, Ulven SM, Retterstøl K, Narverud I, Bogsrud MP, Henriksen T, Bollerslev J, Halvorsen B, Aukrust P, Holven KB (2017)
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study
    Atherosclerosis, 266, 48-57
    DOI 10.1016/j.atherosclerosis.2017.09.021, PubMed 28963918
  6. Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP (2017)
    Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
    J Clin Lipidol, 11 (6), 1338-1346.e7
    DOI 10.1016/j.jacl.2017.08.016, PubMed 28964736
  7. Gjevestad GO, Hamarsland H, Raastad T, Ottestad I, Christensen JJ, Eckardt K, Drevon CA, Biong AS, Ulven SM, Holven KB (2017)
    Gene expression is differentially regulated in skeletal muscle and circulating immune cells in response to an acute bout of high-load strength exercise
    Genes Nutr, 12, 8
    DOI 10.1186/s12263-017-0556-4, PubMed 28270867
  8. Gjevestad GO, Ottestad I, Biong AS, Iversen PO, Retterstøl K, Raastad T, Skålhegg BS, Ulven SM, Holven KB (2017)
    Consumption of protein-enriched milk has minor effects on inflammation in older adults-A 12-week double-blind randomized controlled trial
    Mech Ageing Dev, 162, 1-8
    DOI 10.1016/j.mad.2017.01.011, PubMed 28163108
  9. Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJP, Baccara-Dinet MT, Seiz W, Hamon S, Banerjee P, Stefanutti C (2017)
    Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
    J Clin Lipidol, 12 (2), 390-396.e8
    DOI 10.1016/j.jacl.2017.12.008, PubMed 29396260
  10. Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K (2017)
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia
    Atherosclerosis, 266, 69-73
    DOI 10.1016/j.atherosclerosis.2017.09.027, PubMed 28992466
  11. Hovland A, Nestvold T, Bohov P, Trøseid M, Aukrust P, Berge RK, Waage-Nielsen E, Retterstøl K, Lappegård KT (2017)
    Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals
    Scand J Clin Lab Invest, 77 (8), 628-633
    DOI 10.1080/00365513.2017.1393691, PubMed 29069988
  12. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ (2017)
    Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
    JAMA Cardiol, 2 (6), 598-607
    DOI 10.1001/jamacardio.2017.0747, PubMed 28291870
  13. Mundal LJ (2017)
    Mortalitet og kardiovaskulær morbiditet ved familiær hyperkolesterolemi
    Tidsskr Nor Laegeforen, 137 (3), 225
    DOI 10.4045/tidsskr.16.1015, PubMed 28181769
  14. Narverud I, Christensen JJ, Ottestad IO, Ulven SM, Holven KB (2017)
    Misleading about diet in new national guideline for prevention of cardiovascular disease
    Tidsskr. Nor. Laegeforen., 137 (20), 1584-1586
  15. Narverud I, Christensen JJ, Ottestad IO, Ulven SM, Holven KB (2017)
    [Misleading about diet in a new national guideline for the prevention of cardiovascular disease]
    Tidsskr Nor Laegeforen, 137 (20)
    DOI 10.4045/tidsskr.17.0834, PubMed 29094560
  16. Retterstol K (2017)
    More harm than benefit - how much should the patients know?
    Tidsskr. Nor. Laegeforen., 137 (9), 598
  17. Retterstøl K, Narverud I, Selmer R, Berge KE, Osnes IV, Ulven SM, Halvorsen B, Aukrust P, Holven KB, Iversen PO (2017)
    Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics
    Lipids Health Dis, 16 (1), 115
    DOI 10.1186/s12944-017-0511-9, PubMed 28606150
  18. Svendsen K, Arnesen E, Retterstøl K (2017)
    Saturated fat -a never ending story?
    Food Nutr Res, 61 (1), 1377572
    DOI 10.1080/16546628.2017.1377572, PubMed 29056889
  19. Telle-Hansen VH, Christensen JJ, Ulven SM, Holven KB (2017)
    Does dietary fat affect inflammatory markers in overweight and obese individuals?-a review of randomized controlled trials from 2010 to 2016
    Genes Nutr, 12, 26
    DOI 10.1186/s12263-017-0580-4, PubMed 29043006

Publications 2016

  1. Barrett-Connor E, de Gaetano G, Djoussé L, Ellison RC, Estruch R, Finkel H, Goldfinger T, Keil U, Lanzmann-Petithory D, Mattivi F, Skovenborg E, Stockley C, Svilaas A, Teissedre PL, Thelle DS, Ursini F, Waterhouse AL (2016)
    Comments on Moderate Alcohol Consumption and Mortality
    J Stud Alcohol Drugs, 77 (5), 834-6
    DOI 10.15288/jsad.2016.77.834, PubMed 27588543
  2. Christensen JJ, Osnes L, Halvorsen B, Retterstøl K, Bogsrud MP, Wium C, Svilaas A, Narverud I, Ulven SM, Aukrust P, Holven KB (2016)
    Data on circulating leukocyte subpopulations and inflammatory proteins in children with familial hypercholesterolemia and healthy children
    Data Brief, 10, 587-592
    DOI 10.1016/j.dib.2016.12.042, PubMed 28070551
  3. Christensen JJ, Osnes LT, Halvorsen B, Retterstøl K, Bogsrud MP, Wium C, Svilaas A, Narverud I, Ulven SM, Aukrust P, Holven KB (2016)
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia
    Atherosclerosis, 256, 67-74
    DOI 10.1016/j.atherosclerosis.2016.11.031, PubMed 28024183
  4. Christensen JJ, Retterstøl K, Godang K, Roland MC, Qvigstad E, Bollerslev J, Ueland T, Henriksen T, Holven KB (2016)
    LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors
    J Clin Lipidol, 10 (6), 1369-1378.e7
    DOI 10.1016/j.jacl.2016.08.016, PubMed 27919354
  5. EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiberger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Ceska R, Corral P et al. (2016)
    Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
    Atheroscler Suppl, 22, 1-32
    DOI 10.1016/j.atherosclerosissup.2016.10.001, PubMed 27939304
  6. Halvorsen B, Santilli F, Scholz H, Sahraoui A, Gulseth HL, Wium C, Lattanzio S, Formoso G, Di Fulvio P, Otterdal K, Retterstøl K, Holven KB, Gregersen I, Stavik B, Bjerkeli V, Michelsen AE, Ueland T, Liani R, Davi G, Aukrust P (2016)
    LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
    Diabetologia, 59 (10), 2134-44
    DOI 10.1007/s00125-016-4036-y, PubMed 27421726
  7. Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M (2016)
    Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
    J Clin Lipidol, 11 (1), 195-203.e4
    DOI 10.1016/j.jacl.2016.12.004, PubMed 28391886
  8. Langslet G (2016)
    Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea
    Eur Heart J, 37 (17), 1357-9
    DOI 10.1093/eurheartj/ehw098, PubMed 27026748
  9. Langslet G, Breazna A, Drogari E (2016)
    A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
    J Clin Lipidol, 10 (5), 1153-1162.e3
    DOI 10.1016/j.jacl.2016.05.010, PubMed 27678432
  10. Leiter LA, Langslet G, Vijapurkar U, Davies MJ, Canovatchel W (2016)
    Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
    Diabetes Ther, 7 (2), 269-78
    DOI 10.1007/s13300-016-0163-1, PubMed 26984361
  11. Løvlien M, Mundal L, Hall-Lord ML (2016)
    Health-related quality of life, sense of coherence and leisure-time physical activity in women after an acute myocardial infarction
    J Clin Nurs, 26 (7-8), 975-982
    DOI 10.1111/jocn.13411, PubMed 27239746
  12. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K (2016)
    Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials
    Br J Nutr, 115 (3), 466-79
    DOI 10.1017/S0007114515004699, PubMed 26768850
  13. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K (2016)
    Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD
    Br J Nutr, 115 (12), 2264-6
    DOI 10.1017/S0007114516001343, PubMed 27376624
  14. Mundal L, Igland J, Ose L, Holven KB, Veierød MB, Leren TP, Retterstøl K (2016)
    Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013
    Eur J Prev Cardiol, 24 (2), 137-144
    DOI 10.1177/2047487316676135, PubMed 27794106
  15. Mundal L, Retterstøl K (2016)
    A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries
    Curr Opin Lipidol, 27 (4), 388-97
    DOI 10.1097/MOL.0000000000000300, PubMed 27070076
  16. Mundal L, Veierød MB, Halvorsen T, Holven KB, Ose L, Iversen PO, Tell GS, Leren TP, Retterstøl K (2016)
    Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study
    Eur J Prev Cardiol, 23 (18), 1962-1969
    DOI 10.1177/2047487316666371, PubMed 27558979
  17. Nordstrom M, Paus B, Retterstol K, Kolset SO (2016)
    The prevalence of metabolic risk factors of atherosclerotic cardiovascular disease in Williams syndrome, Prader-Willi syndrome, and Down syndrome
    J. Intellect. Dev. Dis., 41 (3), 187-196
  18. Ottestad I, Nordvi B, Vogt G, Holck M, Halvorsen B, Brønner KW, Retterstøl K, Holven KB, Nilsson A, Ulven SM (2016)
    Bioavailability of n-3 fatty acids from n-3-enriched foods and fish oil with different oxidative quality in healthy human subjects: a randomised single-meal cross-over study
    J Nutr Sci, 5, e43
    DOI 10.1017/jns.2016.34, PubMed 28620470
  19. Pingitore P, Lepore SM, Pirazzi C, Mancina RM, Motta BM, Valenti L, Berge KE, Retterstøl K, Leren TP, Wiklund O, Romeo S (2016)
    Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia
    J Clin Lipidol, 10 (4), 816-823
    DOI 10.1016/j.jacl.2016.02.015, PubMed 27578112
  20. Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ, ODYSSEY CHOICE I investigators (2016)
    A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
    Atherosclerosis, 254, 254-262
    DOI 10.1016/j.atherosclerosis.2016.08.043, PubMed 27639753
  21. Torvik K, Narverud I, Ottestad I, Svilaas A, Gran JM, Retterstøl K, Ellingvåg A, Strøm E, Ose L, Veierød MB, Holven KB (2016)
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia
    Atherosclerosis, 252, 21-27
    DOI 10.1016/j.atherosclerosis.2016.07.913, PubMed 27494447

Publications 2015

  1. Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ, PASCAL Study Group (2015)
    Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
    J Pediatr, 167 (2), 338-43.e5
    DOI 10.1016/j.jpeds.2015.05.006, PubMed 26059337
  2. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Wiegman A, Turner T, Kusters DM, Miller E, Raichlen JS, Wissmar J, Martin PD, Stein EA, Kastelein JJP (2015)
    Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
    J Clin Lipidol, 9 (6), 741-750
    DOI 10.1016/j.jacl.2015.07.011, PubMed 26687694
  3. Gjevestad GO, Holven KB, Ulven SM (2015)
    Effects of Exercise on Gene Expression of Inflammatory Markers in Human Peripheral Blood Cells: A Systematic Review
    Curr Cardiovasc Risk Rep, 9 (7), 34
    DOI 10.1007/s12170-015-0463-4, PubMed 26005511
  4. Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y (2015)
    Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
    Lancet, 385 (9983), 2153-61
    DOI 10.1016/S0140-6736(14)62115-2, PubMed 25743173
  5. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M (2015)
    ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
    Eur Heart J, 36 (43), 2996-3003
    DOI 10.1093/eurheartj/ehv370, PubMed 26330422
  6. Koopal C, Retterstøl K, Sjouke B, Hovingh GK, Ros E, de Graaf J, Dullaart RP, Bertolini S, Visseren FL (2015)
    Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study
    Atherosclerosis, 240 (1), 90-7
    DOI 10.1016/j.atherosclerosis.2015.02.046, PubMed 25768710
  7. Krogh HW, Mundal L, Holven KB, Retterstøl K (2015)
    Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death
    Eur Heart J, 37 (17), 1398-405
    DOI 10.1093/eurheartj/ehv602, PubMed 26586781
  8. Langslet G, Bogsrud MP, Halvorsen I, Fjeldstad H, Retterstøl K, Veierød MB, Ose L (2015)
    Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood
    J Clin Lipidol, 9 (6), 778-785
    DOI 10.1016/j.jacl.2015.08.008, PubMed 26687698
  9. Langslet G, Emery M, Wasserman SM (2015)
    Evolocumab (AMG 145) for primary hypercholesterolemia
    Expert Rev Cardiovasc Ther, 13 (5), 477-88
    DOI 10.1586/14779072.2015.1030395, PubMed 25824308
  10. Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, Leren TP, Retterstøl K (2015)
    [Increased mortality in familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 135 (11), 1024-5
    DOI 10.4045/tidsskr.15.0244, PubMed 26080775
  11. Narverud I, van Lennep JR, Christensen JJ, Versmissen J, Gran JM, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Ulven SM, Ose L, Veierød MB, Sijbrands E, Retterstøl K, Holven KB (2015)
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia
    Atherosclerosis, 243 (1), 155-60
    DOI 10.1016/j.atherosclerosis.2015.09.014, PubMed 26386212
  12. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015)
    Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
    N Engl J Med, 372 (16), 1489-99
    DOI 10.1056/NEJMoa1501031, PubMed 25773378
  13. Schernthaner G, Durán-Garcia S, Hanefeld M, Langslet G, Niskanen L, Östgren CJ, Malvolti E, Hardy E (2015)
    Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
    Diabetes Obes Metab, 17 (7), 630-8
    DOI 10.1111/dom.12461, PubMed 25761977
  14. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK et al. (2015)
    Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
    Eur Heart J, 36 (36), 2425-37
    DOI 10.1093/eurheartj/ehv157, PubMed 26009596

Publications 2014

  1. Berge KE, Retterstøl K, Romeo S, Pirazzi C, Leren TP (2014)
    Type 1 hyperlipoproteinemia due to a novel deletion of exons 3 and 4 in the GPIHBP1 gene
    Atherosclerosis, 234 (1), 30-3
    DOI 10.1016/j.atherosclerosis.2014.02.005, PubMed 24589565
  2. Holven KB, Narverud I, Lindvig HW, Halvorsen B, Langslet G, Nenseter MS, Ulven SM, Ose L, Aukrust P, Retterstøl K (2014)
    Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment
    Atherosclerosis, 233 (2), 561-7
    DOI 10.1016/j.atherosclerosis.2014.01.022, PubMed 24530965
  3. Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT (2014)
    Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies
    Cardiovasc Drugs Ther, 28 (3), 281-9
    DOI 10.1007/s10557-014-6523-z, PubMed 24842558
  4. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G (2014)
    Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
    Diabetes Care, 38 (3), 355-64
    DOI 10.2337/dc13-2762, PubMed 25205142
  5. Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, Leren TP, Retterstøl K (2014)
    Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010
    J Am Heart Assoc, 3 (6), e001236
    DOI 10.1161/JAHA.114.001236, PubMed 25468658
  6. Narverud I, Retterstøl K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, Ose L, Aukrust P, Veierød MB, Holven KB (2014)
    Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review
    Atherosclerosis, 235 (2), 299-309
    DOI 10.1016/j.atherosclerosis.2014.05.917, PubMed 24908240
  7. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014)
    Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
    J Am Coll Cardiol, 63 (13), 1278-1288
    DOI 10.1016/j.jacc.2014.01.006, PubMed 24509273
  8. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators (2014)
    PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    Lancet, 385 (9965), 331-40
    DOI 10.1016/S0140-6736(14)61399-4, PubMed 25282519
  9. Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Öhlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ (2014)
    Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
    Lancet Diabetes Endocrinol, 2 (6), 455-63
    DOI 10.1016/S2213-8587(14)70006-3, PubMed 24731671
  10. Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH et al. (2014)
    Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
    Eur J Hum Genet, 23 (3), 381-7
    DOI 10.1038/ejhg.2014.101, PubMed 24916650

Publications 2013

  1. Baumann M, Espeland MZ, Kværner AS, Bogsrud MP, Retterstøl K (2013)
    [Lipid profile of healthy persons with low-carbohydrate diet]
    Tidsskr Nor Laegeforen, 133 (11), 1193-6
    DOI 10.4045/tidsskr.12.0034, PubMed 23759780
  2. Baumann M, Espeland MZ, Kværner AS, Bogsrud MP, Retterstøl K (2013)
    [M. Baumann and colleagues replies]
    Tidsskr Nor Laegeforen, 133 (16), 1685-6
    DOI 10.4045/tidsskr.13.1023, PubMed 24005696
  3. Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF, Woldseth B, Retterstøl K (2013)
    No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy
    Scand Cardiovasc J, 47 (2), 80-7
    DOI 10.3109/14017431.2012.756119, PubMed 23301875
  4. Bogsrud MP, Reikvam Å, Retterstøl K (2013)
    [Treatment with statins]
    Tidsskr Nor Laegeforen, 133 (12-13), 1316-9
    DOI 10.4045/tidsskr.12.0825, PubMed 23817262
  5. Holven KB, Retterstøl K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, Narverud I, Berge KE, Ose L, Aukrust P, Halvorsen B (2013)
    Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype
    PLoS One, 8 (11), e78241
    DOI 10.1371/journal.pone.0078241, PubMed 24244297
  6. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS, OSLER Investigators (2013)
    Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
    Circulation, 129 (2), 234-43
    DOI 10.1161/CIRCULATIONAHA.113.007012, PubMed 24255061
  7. Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Langslet G, Kastelein JJ, Wiegman A (2013)
    Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia
    J Clin Lipidol, 7 (5), 408-13
    DOI 10.1016/j.jacl.2013.06.010, PubMed 24079281
  8. Langslet G, Ose L (2013)
    Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia
    Expert Rev Cardiovasc Ther, 11 (8), 1061-6
    DOI 10.1586/14779072.2013.814851, PubMed 23984929
  9. Molven I, Retterstøl K, Andersen LF, Veierød MB, Narverud I, Ose L, Svilaas A, Wandel M, Holven KB (2013)
    Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
    J Nutr Sci, 2, e32
    DOI 10.1017/jns.2013.27, PubMed 25191582
  10. Nenseter MS, Aukrust P, Ose L, Holven KB (2013)
    Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy
    Scand J Clin Lab Invest, 74 (1), 1-7
    DOI 10.3109/00365513.2013.854926, PubMed 24236948
  11. Ottestad I, Ose L, Wennersberg MH, Granlund L, Kirkhus B, Retterstøl K (2013)
    Phytosterol capsules and serum cholesterol in hypercholesterolemia: a randomized controlled trial
    Atherosclerosis, 228 (2), 421-5
    DOI 10.1016/j.atherosclerosis.2013.03.001, PubMed 23623012
  12. Stormo C, Bogsrud MP, Hermann M, Åsberg A, Piehler AP, Retterstøl K, Kringen MK (2013)
    UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone
    Mol Diagn Ther, 17 (4), 233-7
    DOI 10.1007/s40291-013-0031-x, PubMed 23580084

Publications 2012

  1. Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP (2012)
    Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways
    Transl Res, 160 (2), 125-30
    DOI 10.1016/j.trsl.2012.01.010, PubMed 22683370
  2. Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, Bryniarski L, Császár A, Vanderbist F (2012)
    Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials
    Clin Drug Investig, 32 (4), 281-91
    DOI 10.2165/11630820-000000000-00000, PubMed 22350498
  3. Farnier M, Retterstøl K, Steinmetz A, Császár A (2012)
    Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
    Diab Vasc Dis Res, 9 (3), 205-15
    DOI 10.1177/1479164111430715, PubMed 22228773
  4. Fretheim A, Odgaard-Jensen J, Brørs O, Madsen S, Njølstad I, Norheim OF, Svilaas A, Kristiansen IS, Thürmer H, Flottorp S (2012)
    Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis
    BMC Med, 10, 33
    DOI 10.1186/1741-7015-10-33, PubMed 22480336
  5. Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L (2012)
    Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia
    J Clin Lipidol, 6 (4), 331-9
    DOI 10.1016/j.jacl.2012.03.004, PubMed 22836070
  6. Narverud I, Halvorsen B, Nenseter MS, Retterstøl K, Yndestad A, Dahl TB, Ulven SM, Olstad OK, Ose L, Holven KB, Aukrust P (2012)
    Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia
    J Intern Med, 273 (1), 69-78
    DOI 10.1111/j.1365-2796.2012.02584.x, PubMed 22891927
  7. Narverud I, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Johansen SG, Nenseter MS, Sandset PM, Ulven SM, Ose L, Retterstøl K, Holven KB (2012)
    Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH
    Thromb Res, 131 (2), 178-82
    DOI 10.1016/j.thromres.2012.11.008, PubMed 23199546
  8. Nenseter MS, Bogsrud MP, Græsdal A, Narverud I, Halvorsen B, Ose L, Aukrust P, Holven KB (2012)
    LDL-apheresis affects markers of endothelial function in patients with homozygous familial hypercholesterolemia
    Thromb Res, 130 (5), 823-5
    DOI 10.1016/j.thromres.2012.06.004, PubMed 22728023
  9. Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Aukrust P, Retterstøl K, Ose L, Halvorsen B, Holven KB (2012)
    Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis
    J Clin Lipidol, 7 (2), 109-16
    DOI 10.1016/j.jacl.2012.08.001, PubMed 23415429
  10. Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Halvorsen B, Ose L, Aukrust P, Holven KB (2012)
    Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis
    Cytokine, 61 (1), 194-8
    DOI 10.1016/j.cyto.2012.09.016, PubMed 23131422
  11. Ottestad I, Retterstøl K, Myhrstad MC, Andersen LF, Vogt G, Nilsson A, Borge GI, Nordvi B, Brønner KW, Ulven SM, Holven KB (2012)
    Intake of oxidised fish oil does not affect circulating levels of oxidised LDL or inflammatory markers in healthy subjects
    Nutr Metab Cardiovasc Dis, 23 (1), e3-4
    DOI 10.1016/j.numecd.2012.08.009, PubMed 23146358
  12. Retterstøl K (2012)
    [Omega-3 fatty acids--both food and medicine]
    Tidsskr Nor Laegeforen, 132 (20), 2258
    DOI 10.4045/tidsskr.12.1006, PubMed 23736186
  13. Telle-Hansen VH, Narverud I, Retterstøl K, Wesseltoft-Rao N, Mosdøl A, Granlund L, Christiansen KF, Lamglait A, Halvorsen B, Holven KB, Ulven SM (2012)
    Substitution of TAG oil with diacylglycerol oil in food items improves the predicted 10 years cardiovascular risk score in healthy, overweight subjects
    J Nutr Sci, 1, e17
    DOI 10.1017/jns.2012.18, PubMed 25191546

Publications 2011

  1. Farnier M, Steinmetz A, Retterstøl K, Császár A (2011)
    Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study
    Clin Ther, 33 (1), 1-12
    DOI 10.1016/j.clinthera.2011.02.006, PubMed 21397769
  2. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L (2011)
    An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
    Pediatr Cardiol, 32 (4), 433-41
    DOI 10.1007/s00246-011-9885-z, PubMed 21259004
  3. Heier I, Søyland E, Krogstad AL, Rodríguez-Gallego C, Nenseter MS, Jahnsen FL (2011)
    Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin
    Br J Dermatol, 165 (4), 792-801
    DOI 10.1111/j.1365-2133.2011.10430.x, PubMed 21623747
  4. Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, Wiegman A (2011)
    Paediatric screening for hypercholesterolaemia in Europe
    Arch Dis Child, 97 (3), 272-6
    DOI 10.1136/archdischild-2011-300081, PubMed 21949015
  5. Myhrstad MC, Narverud I, Telle-Hansen VH, Karhu T, Lund DB, Herzig KH, Makinen M, Halvorsen B, Retterstøl K, Kirkhus B, Granlund L, Holven KB, Ulven SM (2011)
    Effect of the fat composition of a single high-fat meal on inflammatory markers in healthy young women
    Br J Nutr, 106 (12), 1826-35
    DOI 10.1017/S0007114511002510, PubMed 21736782
  6. Myhrstad MC, Retterstøl K, Telle-Hansen VH, Ottestad I, Halvorsen B, Holven KB, Ulven SM (2011)
    Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors
    Inflamm Res, 60 (4), 309-19
    DOI 10.1007/s00011-010-0302-5, PubMed 21229287
  7. Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstøl K (2011)
    Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia
    Atherosclerosis, 216 (2), 426-32
    DOI 10.1016/j.atherosclerosis.2011.02.007, PubMed 21376325
  8. Ose L (2011)
    Pitavastatin: finding its place in therapy
    Ther Adv Chronic Dis, 2 (2), 101-17
    DOI 10.1177/2040622310389227, PubMed 23251745
  9. Ottestad I, Vogt G, Retterstøl K, Myhrstad MC, Haugen JE, Nilsson A, Ravn-Haren G, Nordvi B, Brønner KW, Andersen LF, Holven KB, Ulven SM (2011)
    Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial
    Br J Nutr, 108 (2), 315-26
    DOI 10.1017/S0007114511005484, PubMed 22136711
  10. Skottheim IB, Bogsrud MP, Hermann M, Retterstøl K, Åsberg A (2011)
    Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy
    Mol Diagn Ther, 15 (4), 221-7
    DOI 10.1007/BF03256413, PubMed 21815705
  11. Svilaas A, Strøm EC, Johansen SG, Vebenstad G, Svilaas T, Ose L (2011)
    [Assessment of dietary habits and life style]
    Tidsskr Nor Laegeforen, 131 (5), 454
    DOI 10.4045/tidsskr.10.0799, PubMed 21383795
  12. Søyland E, Heier I, Rodríguez-Gallego C, Mollnes TE, Johansen FE, Holven KB, Halvorsen B, Aukrust P, Jahnsen FL, de la Rosa Carrillo D, Krogstad AL, Nenseter MS (2011)
    Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis
    Br J Dermatol, 164 (2), 344-55
    DOI 10.1111/j.1365-2133.2010.10149.x, PubMed 21271993
  13. Toleikyte I, Retterstøl K, Leren TP, Iversen PO (2011)
    Pregnancy outcomes in familial hypercholesterolemia: a registry-based study
    Circulation, 124 (15), 1606-14
    DOI 10.1161/CIRCULATIONAHA.110.990929, PubMed 21911783

Publications 2010

  1. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA (2010)
    Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia
    J Am Coll Cardiol, 55 (11), 1121-6
    DOI 10.1016/j.jacc.2009.10.042, PubMed 20223367
  2. Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K (2010)
    HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study
    Scand Cardiovasc J, 44 (4), 197-200
    DOI 10.3109/14017431003624123, PubMed 20636227
  3. Kulseth MA, Berge KE, Bogsrud MP, Leren TP (2010)
    Analysis of LDLR mRNA in patients with familial hypercholesterolemia revealed a novel mutation in intron 14, which activates a cryptic splice site
    J Hum Genet, 55 (10), 676-80
    DOI 10.1038/jhg.2010.87, PubMed 20703241
  4. Langslet G, Ottestad I, Retterstøl K, Ose L (2010)
    [Clinical trials--viewpoints from participants]
    Tidsskr Nor Laegeforen, 130 (16), 1606-8
    DOI 10.4045/tidsskr.09.0030, PubMed 20805857
  5. Narverud I, Ueland T, Nenseter MS, Retterstøl K, Telle-Hansen VH, Halvorsen B, Ose L, Aukrust P, Holven KB (2010)
    Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10
    Atherosclerosis, 214 (1), 163-8
    DOI 10.1016/j.atherosclerosis.2010.10.002, PubMed 21040915
  6. Ose L (2010)
    Pitavastatin: a distinctive lipid-lowering drug
    Clin. Lipidol., 5 (3), 309-323
  7. Ose L, Budinski D, Hounslow N, Arneson V (2010)
    Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia (vol 210, pg 202, 2010)
    Atherosclerosis, 212 (2), 704
  8. Sakhi AK, Bøhn SK, Smeland S, Thoresen M, Smedshaug GB, Tausjø J, Svilaas A, Karlsen A, Russnes KM, Svilaas T, Blomhoff R (2010)
    Postradiotherapy plasma lutein, alpha-carotene, and beta-carotene are positively associated with survival in patients with head and neck squamous cell carcinoma
    Nutr Cancer, 62 (3), 322-8
    DOI 10.1080/01635580903441188, PubMed 20358469
  9. Solaas K, Legry V, Retterstol K, Berg PR, Holven KB, Ferrières J, Amouyel P, Lien S, Romeo J, Valtueña J, Widhalm K, Ruiz JR, Dallongeville J, Tonstad S, Rootwelt H, Halvorsen B, Nenseter MS, Birkeland KI, Thorsby PM, Meirhaeghe A, Nebb HI (2010)
    Suggestive evidence of associations between liver X receptor β polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe)
    BMC Med Genet, 11, 144
    DOI 10.1186/1471-2350-11-144, PubMed 20939869

Publications 2009

  1. Graesdal A (2009)
    [Use of omega-3 fatty acids in the prevention of heart disease]
    Tidsskr Nor Laegeforen, 129 (20), 2109-12
    DOI 10.4045/tidsskr.08.0447, PubMed 19855449
  2. Khoury J, Amundsen AL, Tonstad S, Henriksen T, Ose L, Retterstøl K, Iversen PO (2009)
    Evidence for impaired physiological decrease in the uteroplacental vascular resistance in pregnant women with familial hypercholesterolemia
    Acta Obstet Gynecol Scand, 88 (2), 222-6
    DOI 10.1080/00016340802503047, PubMed 18972234
  3. Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA, CAPTIVATE Investigators (2009)
    ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial
    JAMA, 301 (11), 1131-9
    DOI 10.1001/jama.301.11.1131, PubMed 19293413
  4. Ose L, Budinski D, Hounslow N, Arneson V (2009)
    Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia
    Atherosclerosis, 210 (1), 202-8
    DOI 10.1016/j.atherosclerosis.2009.12.009, PubMed 20080236
  5. Ose L, Budinski D, Hounslow N, Arneson V (2009)
    Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
    Curr Med Res Opin, 25 (11), 2755-64
    DOI 10.1185/03007990903290886, PubMed 19785568
  6. Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal Torjesen P, Hagve TA, Nenseter MS, Krogstad AL (2009)
    Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis
    J Eur Acad Dermatol Venereol, 23 (10), 1133-40
    DOI 10.1111/j.1468-3083.2009.03245.x, PubMed 19453805
  7. Retterstøl K (2009)
    Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
    Expert Opin Investig Drugs, 18 (9), 1405-11
    DOI 10.1517/13543780903164205, PubMed 19678802
  8. Retterstøl K, Hennig CB, Iversen PO (2009)
    Improved plasma lipids and body weight in overweight/obese patients with type III hyperlipoproteinemia after 4 weeks on a low glycemic diet
    Clin Nutr, 28 (2), 213-5
    DOI 10.1016/j.clnu.2009.01.018, PubMed 19232793
  9. Tobin KA, Holven KB, Retterstøl K, Strøm E, Ose L, Aukrust P, Nenseter MS (2009)
    Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins
    Br J Nutr, 102 (12), 1783-9
    DOI 10.1017/S0007114509991048, PubMed 19682403
  10. Wennersberg MH, Smedman A, Turpeinen AM, Retterstøl K, Tengblad S, Lipre E, Aro A, Mutanen P, Seljeflot I, Basu S, Pedersen JI, Mutanen M, Vessby B (2009)
    Dairy products and metabolic effects in overweight men and women: results from a 6-mo intervention study
    Am J Clin Nutr, 90 (4), 960-8
    DOI 10.3945/ajcn.2009.27664, PubMed 19710195

Publications 2008

  1. Blom DJ, Marais AD, Retterstøl K, Stein EA, Ycas J, Gu Z, Miller E (2008)
    Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia)
    J Clin Lipidol, 2 (6), 418-25
    DOI 10.1016/j.jacl.2008.10.002, PubMed 21291775
  2. Graesdal A (2008)
    [Severe hypertriglyceridemia--an important cause of pancreatitis]
    Tidsskr Nor Laegeforen, 128 (9), 1053-6
    PubMed 18451886
  3. Holven KB, Aukrust P, Retterstøl K, Otterdal K, Bjerkeli V, Ose L, Nenseter MS, Halvorsen B (2008)
    The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects
    J Nutr, 138 (11), 2070-5
    DOI 10.3945/jn.108.090704, PubMed 18936200
  4. Langslet G, Reikvam A (2008)
    [Can cardiovascular events be prevented by raising HDL cholesterol?]
    Tidsskr Nor Laegeforen, 128 (13), 1519-23
    PubMed 18587459
  5. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE (2008)
    Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening
    Community Genet, 11 (1), 26-35
    DOI 10.1159/000111637, PubMed 18196915
  6. Nenseter MS, Ueland T, Retterstøl K, Strøm E, Mørkrid L, Landaas S, Ose L, Aukrust P, Holven KB (2008)
    Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: effect of treatment with B-vitamins
    Stroke, 40 (1), 241-7
    DOI 10.1161/STROKEAHA.108.522995, PubMed 19008470
  7. Ose L (2008)
    The real code of leonardo da vinci
    Curr Cardiol Rev, 4 (1), 60-2
    DOI 10.2174/157340308783565401, PubMed 19924278
  8. Retterstøl K (2008)
    [The zero vision for arteriosclerotic cardiovascular disease in younger people]
    Tidsskr Nor Laegeforen, 128 (10), 1188-90
    PubMed 18480870
  9. Svilaas A, Strandberg T, Eriksson M, Hildebrandt P, Westheim A (2008)
    Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia
    Scand Cardiovasc J, 42 (4), 279-87
    DOI 10.1080/14017430802073073, PubMed 18609053

Publications 2007

  1. Bogsrud MP, Sogstad A, Retterstøl K (2007)
    [Practical advice for registration of clinical trials]
    Tidsskr Nor Laegeforen, 127 (12), 1654-6
    PubMed 17571106
  2. Feldman T, Ose L, Shah A, Zakson M, Meehan A, Johnson-Levonas AO, Maccubbin D, Tribble DL, Veltri E, Mitchel Y (2007)
    Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome
    Metab Syndr Relat Disord, 5 (1), 13-21
    DOI 10.1089/met.2006.0033, PubMed 18370810
  3. Frich JC, Malterud K, Fugelli P (2007)
    Experiences of guilt and shame in patients with familial hypercholesterolemia: a qualitative interview study
    Patient Educ Couns, 69 (1-3), 108-13
    DOI 10.1016/j.pec.2007.08.001, PubMed 17889493
  4. Leren TP, Manshaus TE, Ose L, Berge KE (2007)
    [Lipid profile in children and adolescents with familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 127 (18), 2363-6
    PubMed 17895939
  5. Lilleby V, Haugen M, Mørkrid L, Frey Frøslie K, Holven KB, Førre O (2007)
    Body composition, lipid and lipoprotein levels in childhood-onset systemic lupus erythematosus
    Scand J Rheumatol, 36 (1), 40-7
    DOI 10.1080/03009740600907881, PubMed 17454934
  6. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T, Vytorin Extension Study Group (2007)
    A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet
    Int J Clin Pract, 61 (9), 1469-80
    DOI 10.1111/j.1742-1241.2007.01402.x, PubMed 17655686
  7. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T (2007)
    Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques
    Clin Ther, 29 (11), 2419-32
    DOI 10.1016/j.clinthera.2007.10.004, PubMed 18158082
  8. Stein EA, Ose L, Retterstøl K, Tonstad S, Schleman M, Harris S, Sager P (2007)
    Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia
    J Clin Lipidol, 1 (4), 280-6
    DOI 10.1016/j.jacl.2007.07.003, PubMed 21291692
  9. Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M (2007)
    The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
    Metabolism, 56 (9), 1285-92
    DOI 10.1016/j.metabol.2007.05.003, PubMed 17697874

Publications 2006

  1. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstøl K (2006)
    Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia
    Atherosclerosis, 189 (2), 451-7
    DOI 10.1016/j.atherosclerosis.2006.01.002, PubMed 16466729
  2. Amundsen AL, Khoury J, Sandset PM, Seljeflot I, Ose L, Tonstad S, Henriksen T, Retterstøl K, Iversen PO (2006)
    Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
    Thromb Res, 120 (1), 21-7
    DOI 10.1016/j.thromres.2006.07.001, PubMed 16914186
  3. Berge KE, Ose L, Leren TP (2006)
    Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
    Arterioscler Thromb Vasc Biol, 26 (5), 1094-100
    DOI 10.1161/01.ATV.0000204337.81286.1c, PubMed 16424354
  4. Frich JC, Ose L, Malterud K, Fugelli P (2006)
    Perceived vulnerability to heart disease in patients with familial hypercholesterolemia: a qualitative interview study
    Ann Fam Med, 4 (3), 198-204
    DOI 10.1370/afm.529, PubMed 16735520
  5. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K (2006)
    Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
    Clin Pharmacol Ther, 79 (6), 532-9
    DOI 10.1016/j.clpt.2006.02.014, PubMed 16765141
  6. Holven KB, Aukrust P, Pedersen TM, Ose L, Nenseter MS (2006)
    Enhanced platelet activation in hyperhomocysteinemic individuals
    J Thromb Haemost, 5 (1), 193-5
    DOI 10.1111/j.1538-7836.2006.02275.x, PubMed 17059422
  7. Holven KB, Aukrust P, Retterstol K, Hagve TA, Mørkrid L, Ose L, Nenseter MS (2006)
    Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects
    Scand J Clin Lab Invest, 66 (1), 45-54
    DOI 10.1080/00335510500429821, PubMed 16464786
  8. Holven KB, Halvorsen B, Bjerkeli V, Damås JK, Retterstøl K, Mørkrid L, Ose L, Aukrust P, Nenseter MS (2006)
    Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects
    Stroke, 37 (7), 1731-6
    DOI 10.1161/01.STR.0000226465.84561.cb, PubMed 16728689
  9. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y (2006)
    Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis
    Curr Med Res Opin, 22 (5), 823-35
    DOI 10.1185/030079906X100131, PubMed 16709304
  10. Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgström F, Jönsson L (2006)
    Lipid management and cholesterol goal attainment in Norway
    Am J Cardiovasc Drugs, 6 (2), 121-8
    DOI 10.2165/00129784-200606020-00006, PubMed 16555865
  11. Ottestad IO, Halvorsen B, Balstad TR, Otterdal K, Borge GI, Brosstad F, Myhre AM, Ose L, Nenseter MS, Holven KB (2006)
    Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux
    J Nutr, 136 (4), 877-81
    DOI 10.1093/jn/136.4.877, PubMed 16549444
  12. Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG (2006)
    Increased inflammatory markers in children with familial hypercholesterolaemia
    Eur J Clin Invest, 36 (3), 147-52
    DOI 10.1111/j.1365-2362.2006.01613.x, PubMed 16506958

Publications 2005

  1. Balstad TR, Holven KB, Ottestad IO, Otterdal K, Halvorsen B, Myhre AM, Ose L, Nenseter MS (2005)
    Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function
    Clin Chim Acta, 359 (1-2), 171-8
    DOI 10.1016/j.cccn.2005.03.050, PubMed 15936009
  2. Bøhn SK, Smeland S, Sakhi AK, Thoresen M, Russnes KM, Tausjø J, Svilaas A, Svilaas T, Blomhoff R (2005)
    Post-radiotherapy plasma total glutathione is associated to outcome in patients with head and neck squamous cell carcinoma
    Cancer Lett, 238 (2), 240-7
    DOI 10.1016/j.canlet.2005.07.027, PubMed 16157445
  3. Holven KB, Damås JK, Yndestad A, Waehre T, Ueland T, Halvorsen B, Heggelund L, Sandberg WJ, Semb AG, Frøland SS, Ose L, Nenseter MS, Aukrust P (2005)
    Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES
    Arterioscler Thromb Vasc Biol, 26 (1), 200-5
    DOI 10.1161/01.ATV.0000193619.67288.ed, PubMed 16254204
  4. Retterstøl K (2005)
    Too low blood cholesterol?
    Scand J Clin Lab Invest, 65 (1), 1-2
    DOI 10.1080/00365510510013488, PubMed 15859021
  5. Staff AC, Holven K, Løken EB, Sygnestveit K, Vollset SE, Smeland S (2005)
    [Does folic acid have effects on other health problems than neural tube defects?]
    Tidsskr Nor Laegeforen, 125 (4), 438-41
    PubMed 15742017
  6. Staff AC, Løken EB, Holven K, Sygnestveit K, Vollset SE, Smeland S (2005)
    [Effects of public initiatives aimed at reducing neural tube defects with folic acid supplementation]
    Tidsskr Nor Laegeforen, 125 (4), 435-7
    PubMed 15742016
  7. Westerberg R, Månsson JE, Golozoubova V, Shabalina IG, Backlund EC, Tvrdik P, Retterstøl K, Capecchi MR, Jacobsson A (2005)
    ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue
    J Biol Chem, 281 (8), 4958-68
    DOI 10.1074/jbc.M511588200, PubMed 16326704

Publications 2004

  1. Amundsen AL, Ntanios F, Put Nv, Ose L (2004)
    Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread
    Eur J Clin Nutr, 58 (12), 1612-20
    DOI 10.1038/sj.ejcn.1602015, PubMed 15199384
  2. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group (2004)
    A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
    Clin Ther, 26 (11), 1758-73
    DOI 10.1016/j.clinthera.2004.11.016, PubMed 15639688
  3. Blomhoff S, Holven KB, Brosstad F, Ose L, Nenseter MS (2004)
    Psychological factors and cardiovascular disease
    J Thromb Haemost, 2 (1), 201-3
    DOI 10.1111/j.1538-7836.2004.0562g.x, PubMed 14717990
  4. Hexeberg S, Retterstøl K (2004)
    [Hypertriglyceridemia--diagnostics, risk and treatment]
    Tidsskr Nor Laegeforen, 124 (21), 2746-9
    PubMed 15534665
  5. Leren TP, Manshaus T, Ose L (2004)
    [A family-based strategy for diagnosing familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 124 (9), 1228-9
    PubMed 15131703
  6. Ose L (2004)
    Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children
    Semin Vasc Med, 4 (1), 51-7
    DOI 10.1055/s-2004-822986, PubMed 15199433
  7. Svilaas A, Sakhi AK, Andersen LF, Svilaas T, Ström EC, Jacobs DR, Ose L, Blomhoff R (2004)
    Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans
    J Nutr, 134 (3), 562-7
    DOI 10.1093/jn/134.3.562, PubMed 14988447
  8. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Frøland SS, Semb AG, Aukrust P, Damås JK (2004)
    Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors
    Circulation, 109 (16), 1966-72
    DOI 10.1161/01.CIR.0000125700.33637.B1, PubMed 15051633

Publications 2003

  1. Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, Maccubbin DL, Mercuri M (2003)
    Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Clin Cardiol, 26 (11), 509-14
    DOI 10.1002/clc.4960261106, PubMed 14640465
  2. Fretheim A, Oxman AD, Bjørndal A, Dyrdal A, Golding M, Ose L, Reikvam D, Teisberg P (2003)
    [Shortcomings and strength of practice guidelines]
    Tidsskr Nor Laegeforen, 123 (11), 1566-7
    PubMed 12822025
  3. Holm T, Damås JK, Holven K, Nordøy I, Brosstad FR, Ueland T, Währe T, Kjekshus J, Frøland SS, Eiken HG, Solum NO, Gullestad L, Nenseter M, Aukrust P (2003)
    CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells
    J Thromb Haemost, 1 (2), 257-62
    DOI 10.1046/j.1538-7836.2003.00065.x, PubMed 12871498
  4. Holven KB, Halvorsen B, Schulz H, Aukrust P, Ose L, Nenseter MS (2003)
    Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects
    Eur J Clin Invest, 33 (7), 555-60
    DOI 10.1046/j.1365-2362.2003.01189.x, PubMed 12814391
  5. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS (2003)
    Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects
    Br J Nutr, 89 (3), 359-63
    DOI 10.1079/BJN2002779, PubMed 12628031
  6. Holven KB, Myhre AM, Aukrust P, Hagve TA, Ose L, Nenseter MS (2003)
    Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo. Dependency of xanthomas/xanthelasms, smoking and gender
    Eur Heart J, 24 (19), 1756-62
    DOI 10.1016/s0195-668x(03)00467-6, PubMed 14522571
  7. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS (2003)
    Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells
    J Nutr, 133 (11), 3588-91
    DOI 10.1093/jn/133.11.3588, PubMed 14608078
  8. McCrindle BW, Ose L, Marais AD (2003)
    Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial
    J Pediatr, 143 (1), 74-80
    DOI 10.1016/S0022-3476(03)00186-0, PubMed 12915827

Publications 2002

  1. Amundsen AL, Ose L, Nenseter MS, Ntanios FY (2002)
    Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia
    Am J Clin Nutr, 76 (2), 338-44
    DOI 10.1093/ajcn/76.2.338, PubMed 12145004
  2. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ, Simvastatin in Children Study Group (2002)
    Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin
    Circulation, 106 (17), 2231-7
    DOI 10.1161/01.cir.0000035247.42888.82, PubMed 12390953
  3. Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
    [Guidelines for pharmacological primary prevention of cardiovascular diseases--who should be treated?]
    Tidsskr Nor Laegeforen, 122 (23), 2277-81
    PubMed 12448268
  4. Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
    [Which antihypertensive drugs should be used in the primary prevention of cardiovascular disease?]
    Tidsskr Nor Laegeforen, 122 (23), 2283-6
    PubMed 12448269
  5. Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P (2002)
    [Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease?]
    Tidsskr Nor Laegeforen, 122 (23), 2287-8
    PubMed 12448270
  6. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS (2002)
    Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects
    Arterioscler Thromb Vasc Biol, 22 (4), 699-703
    DOI 10.1161/01.atv.0000013288.35930.90, PubMed 11950713
  7. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group (2002)
    Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
    Am Heart J, 144 (6), 1044-51
    DOI 10.1067/mhj.2002.128049, PubMed 12486429
  8. Ose L (2002)
    [Müller-Harbitz disease--familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 122 (9), 924-5
    PubMed 12082837
  9. Ose L (2002)
    Familial hypercholesterolemia from children to adults
    Cardiovasc Drugs Ther, 16 (4), 289-93
    DOI 10.1023/a:1021773724477, PubMed 12652097
  10. Svilaas A, Ström EC, Svilaas T, Borgejordet A, Thoresen M, Ose L (2002)
    Reproducibility and validity of a short food questionnaire for the assessment of dietary habits
    Nutr Metab Cardiovasc Dis, 12 (2), 60-70
    PubMed 12189905

Publications 2001

  1. Asmussen I, Mundal L (2001)
    [Transesophageal echocardiography at a small Norwegian district hospital]
    Tidsskr Nor Laegeforen, 121 (5), 572-4
    PubMed 11301612
  2. Guttormsen AB, Ueland PM, Kruger WD, Kim CE, Ose L, Følling I, Refsum H (2001)
    Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype
    Am J Med Genet, 100 (3), 204-13
    DOI 10.1002/ajmg.1247, PubMed 11343305
  3. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS (2001)
    Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects
    Am J Med, 110 (7), 536-42
    DOI 10.1016/s0002-9343(01)00696-9, PubMed 11343667
  4. Lee MH, Gordon D, Ott J, Lu K, Ose L, Miettinen T, Gylling H, Stalenhoef AF, Pandya A, Hidaka H, Brewer B, Kojima H, Sakuma N, Pegoraro R, Salen G, Patel SB (2001)
    Fine mapping of a gene responsible for regulating dietary cholesterol absorption; founder effects underlie cases of phytosterolaemia in multiple communities
    Eur J Hum Genet, 9 (5), 375-84
    DOI 10.1038/sj.ejhg.5200628, PubMed 11378826
  5. Leren TP, Tonstad S, Ose L (2001)
    [Genetic screening and treatment in familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 121 (13), 1635-6
    PubMed 11446055
  6. Leren TP, Tonstad S, Ose L (2001)
    [Familial hypercholesterolemia--prognosis and treatment]
    Tidsskr Nor Laegeforen, 121 (13), 1635
    PubMed 11446054
  7. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB, Salen G, Dean M, Srivastava A, Patel SB (2001)
    Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively
    Am J Hum Genet, 69 (2), 278-90
    DOI 10.1086/321294, PubMed 11452359
  8. Svilaas A, Ose L, Risberg K, Thoresen M (2001)
    [Treatment goals for blood lipids in high risk patients of atherosclerotic disease]
    Tidsskr Nor Laegeforen, 121 (9), 1059-63
    PubMed 11354882
  9. Tonstad S, Strøm EC, Bergei CS, Ose L, Christophersen B (2001)
    Serum cholesterol response to replacing butter with a new trans-free margarine in hypercholesterolemic subjects
    Nutr Metab Cardiovasc Dis, 11 (5), 320-6
    PubMed 11887429
  10. Tran TN, Retterstøl K, Christophersen BO (2001)
    Differences in the conversion of the polyunsaturated fatty acids [1-(14)C]22:4(n-6) and [1-(14)C]22:5(n-3) to [(14)C]22:5(n-6) and [(14)C]22:6(n-3) in isolated rat hepatocytes
    Biochim Biophys Acta, 1532 (1-2), 137-47
    DOI 10.1016/s1388-1981(01)00127-5, PubMed 11420183

Publications 2000

  1. Asmussen I, Mundal L (2000)
    [Cardiologic procedures at a smaller Norwegian hospital--educational potential for assistant residents]
    Tidsskr Nor Laegeforen, 120 (18), 2192
    PubMed 11006748
  2. Björn Lundahl, Leren TP, Ose L, Hamsten A, Karpe F (2000)
    A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia
    Arterioscler Thromb Vasc Biol, 20 (7), 1784-8
    DOI 10.1161/01.atv.20.7.1784, PubMed 10894817
  3. Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W, Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campodónico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB, Worldwide Expanded Dose Simvastatin Study Group (2000)
    Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia
    Nutr Metab Cardiovasc Dis, 10 (5), 253-62
    PubMed 11213534
  4. Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB (2000)
    Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
    Am J Cardiol, 86 (2), 221-3
    DOI 10.1016/s0002-9149(00)00942-5, PubMed 10913488
  5. Nenseter MS, Østerud B, Larsen T, Strøm E, Bergei C, Hewitt S, Holven KB, Hagve TA, Mjøs SA, Solvang M, Pettersen J, Opstvedt J, Ose L (2000)
    Effect of Norwegian fish powder on risk factors for coronary heart disease among hypercholesterolemic individuals
    Nutr Metab Cardiovasc Dis, 10 (6), 323-30
    PubMed 11302007
  6. Ose L, Davidson MH, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB (2000)
    Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group
    Clin Cardiol, 23 (1), 39-46
    DOI 10.1002/clc.4960230108, PubMed 10680028
  7. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B (2000)
    Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group
    Curr Med Res Opin, 16 (2), 80-7
    PubMed 10893651
  8. Svilaas A, Bergei CS, Strøm EC, Ose L, Walsøe HK (2000)
    [The diet of patients with atherosclerotic disease compared with the standard diet in the population]
    Tidsskr Nor Laegeforen, 120 (22), 2618-24
    PubMed 11077504
  9. Svilaas A, Risberg K, Thoresen M, Ose L (2000)
    Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice
    Am J Cardiol, 86 (11), 1250-3, A6
    DOI 10.1016/s0002-9149(00)01212-1, PubMed 11090801
  10. Svilaas A, Walsöe HK, Ose L (2000)
    Application of simple lipid treatment goals in patients with atherosclerotic disease
    Nutr Metab Cardiovasc Dis, 10 (2), 71-8
    PubMed 10919171
  11. Tonstad S, Joakimsen O, Leren TP, Ose L (2000)
    Does maternal or paternal heredity affect carotid atherosclerosis in children with familial hypercholesterolaemia?
    Acta Paediatr, 89 (12), 1490-2
    DOI 10.1080/080352500456705, PubMed 11195242

Publications 1999

  1. Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA (1999)
    Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
    Am J Cardiol, 83 (10), 1476-7, A7
    DOI 10.1016/s0002-9149(99)00153-8, PubMed 10335764
  2. Hanefeld M, Deslypere JP, Ose L, Durrington PN, Farnier M, Schmage N (1999)
    Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study
    J Int Med Res, 27 (3), 115-29
    DOI 10.1177/030006059902700302, PubMed 10505301
  3. Myhre AM, Holven KB, Norum KR, Blomhoff R (1999)
    Retinoylation of proteins in rat hepatocytes following uptake of chylomicron remnant retinyl ester
    Scand J Clin Lab Invest, 59 (5), 315-24
    DOI 10.1080/00365519950185508, PubMed 10533843
  4. Ose L (1999)
    An update on familial hypercholesterolaemia
    Ann Med, 31 Suppl 1, 13-8
    PubMed 10342495
  5. Ose L (1999)
    An update on familial hypercholesterolaemia
    Ann Med, 31 (sup1), 13-18
    DOI 10.1080/07853890.1999.11904394, PubMed 28850282
  6. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B (1999)
    Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group
    Curr Med Res Opin, 15 (3), 228-40
    DOI 10.1185/03007999909114095, PubMed 10621930
  7. Rødningen OK, Tonstad S, Medh JD, Chappell DA, Ose L, Leren TP (1999)
    Phenotypic consequences of a deletion of exons 2 and 3 of the LDL receptor gene
    J Lipid Res, 40 (2), 213-20
    PubMed 9925649
  8. Rødningen OK, Tonstad S, Saugstad OD, Ose L, Leren TP (1999)
    Mutant transcripts of the LDL receptor gene: mRNA structure and quantity
    Hum Mutat, 13 (3), 186-96
    DOI 10.1002/(SICI)1098-1004(1999)13:3<186::AID-HUMU2>3.0.CO;2-K, PubMed 10090473
  9. Tonstad S, Gørbitz C, Sivertsen M, Ose L (1999)
    Under-reporting of dietary intake by smoking and non-smoking subjects counselled for hypercholesterolaemia
    J Intern Med, 245 (4), 337-44
    DOI 10.1046/j.1365-2796.1999.00450.x, PubMed 10356595

Publications 1998

  1. Davignon J, Hanefeld M, Nakaya N, Hunninghake DB, Insull W, Ose L (1998)
    Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies
    Am J Cardiol, 82 (4B), 32J-39J
    DOI 10.1016/s0002-9149(98)00435-4, PubMed 9737644
  2. Ose L, Kastelein JJP, Scott R, Stein EA, Campodonico S, Escobar ID, Tate AC, Corsetti L, Shahane A, Mitchel YB, Mercuri M, WSEDP Res Grp (1998)
    Efficacy and six-month safety of simvastatin 80 mg/day: Results from the worldwide simvastatin expanded dose program (WSEDP)
    Nutr. Metab. Carbiovasc. Dis., 8 (3), 135-143
  3. Ose L, Vollebaek LE, Tonstad S (1998)
    [Attitude to genetic screening for familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 118 (10), 1578-81
    PubMed 9615587
  4. Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1998)
    Effects of a 9.6-kb deletion of the LDL receptor gene (FH Helsinki) on structure and levels of mRNA
    Hum Mutat, 12 (2), 95-102
    DOI 10.1002/(SICI)1098-1004(1998)12:2<95::AID-HUMU4>3.0.CO;2-E, PubMed 9671270
  5. Sundt E, Ose L, Tonstad S (1998)
    [Referrals to the Lipid clinic--"appropriate" patients with inadequate anamnesis]
    Tidsskr Nor Laegeforen, 118 (5), 749-52
    PubMed 9528374
  6. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bønaa KH, Leren TP (1998)
    Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects
    Eur J Clin Invest, 28 (12), 971-9
    DOI 10.1046/j.1365-2362.1998.00399.x, PubMed 9893006
  7. Tonstad S, Refsum H, Ose L, Ueland PM (1998)
    The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine
    J Pediatr, 132 (2), 365-8
    DOI 10.1016/s0022-3476(98)70465-2, PubMed 9506661
  8. Ulven SM, Natarajan V, Holven KB, Løvdal T, Berg T, Blomhoff R (1998)
    Expression of retinoic acid receptor and retinoid X receptor subtypes in rat liver cells: implications for retinoid signalling in parenchymal, endothelial, Kupffer and stellate cells
    Eur J Cell Biol, 77 (2), 111-6
    DOI 10.1016/S0171-9335(98)80078-2, PubMed 9840460
  9. Woldseth B, Retterstøl K, Christophersen BO (1998)
    Monounsaturated trans fatty acids, elaidic acid and trans-vaccenic acid, metabolism and incorporation in phospholipid molecular species in hepatocytes
    Scand J Clin Lab Invest, 58 (8), 635-45
    DOI 10.1080/00365519850186067, PubMed 10088200

Publications 1997

  1. Kim CE, Gallagher PM, Guttormsen AB, Refsum H, Ueland PM, Ose L, Folling I, Whitehead AS, Tsai MY, Kruger WD (1997)
    Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria
    Hum Mol Genet, 6 (13), 2213-21
    DOI 10.1093/hmg/6.13.2213, PubMed 9361025
  2. Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A (1997)
    Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I
    J Lipid Res, 38 (1), 121-31
    PubMed 9034206
  3. Leren TP, Bakken KS, Rødningen OK, Gundersen KE, Sundvold H, Berg K, Tonstad S, Ose L (1997)
    [Application of gene technology in the diagnosis of familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 117 (5), 678-81
    PubMed 9102960
  4. Leren TP, Ose L (1997)
    [Is there a need for genetic/molecular diagnosis of familial hypercholesterolemia?]
    Tidsskr Nor Laegeforen, 117 (5), 681-3
    PubMed 9102961
  5. Leren TP, Tonstad S, Gundersen KE, Bakken KS, Rødningen OK, Sundvold H, Ose L, Berg K (1997)
    Molecular genetics of familial hypercholesterolaemia in Norway
    J Intern Med, 241 (3), 185-94
    DOI 10.1046/j.1365-2796.1997.78119000.x, PubMed 9104431
  6. Nagy NE, Holven KB, Roos N, Senoo H, Kojima N, Norum KR, Blomhoff R (1997)
    Storage of vitamin A in extrahepatic stellate cells in normal rats
    J Lipid Res, 38 (4), 645-58
    PubMed 9144080
  7. Svilaas A, Bye P, Strøm EC, Kolbjørnsen O, Tonstad S, Ose L (1997)
    [What happens with patients after participation in a clinical trial?]
    Tidsskr Nor Laegeforen, 117 (28), 4065-9
    PubMed 9441437
  8. Tonstad S (1997)
    Correlates of plasma total homocysteine in patients with hyperlipidaemia
    Eur J Clin Invest, 27 (12), 1025-9
    DOI 10.1046/j.1365-2362.1997.2260772.x, PubMed 9466131
  9. Tonstad S (1997)
    [Drug therapy of hyperlipidemia--unanswered questions]
    Tidsskr Nor Laegeforen, 117 (5), 674-7
    PubMed 9102959
  10. Tonstad S, Leren TP, Ose L (1997)
    [Diagnosis and treatment of severe hyperlipidemia]
    Tidsskr Nor Laegeforen, 117 (29), 4241-4
    PubMed 9441469
  11. Tonstad S, Refsum H, Ueland PM (1997)
    Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia
    Circulation, 96 (6), 1803-8
    DOI 10.1161/01.cir.96.6.1803, PubMed 9323065
  12. Urdal P, Leren TP, Tonstad S, Lund PK, Ose L (1997)
    Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia
    Cytometry, 30 (5), 264-8
    PubMed 9383100

Publications 1996

  1. Gundersen KE, Solberg K, Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1996)
    Two novel missense mutations in the LDL receptor gene causing familial hypercholesterolemia
    Clin Genet, 49 (2), 85-7
    DOI 10.1111/j.1399-0004.1996.tb04333.x, PubMed 8740918
  2. Halvorsen B, Brude I, Drevon CA, Nysom J, Ose L, Christiansen EN, Nenseter MS (1996)
    Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein
    J Lipid Res, 37 (7), 1591-600
    PubMed 8827529
  3. Leren TP, Sundvold H, Rodningen OK, Tonstad S, Solberg K, Ose L, Berg K (1996)
    Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia (vol 95, pg 671, 1995)
    Hum. Genet., 97 (2), 268
  4. Lütjohann D, Björkhem I, Ose L (1996)
    Phytosterolaemia in a Norwegian family: diagnosis and characterization of the first Scandinavian case
    Scand J Clin Lab Invest, 56 (3), 229-40
    DOI 10.3109/00365519609088612, PubMed 8761527
  5. Natarajan V, Holven KB, Reppe S, Blomhoff R, Moskaug JO (1996)
    The C-terminal RNLL sequence of the plasma retinol-binding protein is not responsible for its intracellular retention
    Biochem Biophys Res Commun, 221 (2), 374-9
    DOI 10.1006/bbrc.1996.0603, PubMed 8619863
  6. Nenseter MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S (1996)
    Effect of hormone replacement therapy on the susceptibility of low-density lipoprotein to oxidation among postmenopausal hypercholesterolaemic women
    Eur J Clin Invest, 26 (12), 1062-8
    DOI 10.1046/j.1365-2362.1996.390593.x, PubMed 9013080
  7. Ose L (1996)
    Simvastatin-fluvastatin comparative study - Reply
    Clin. Drug Invest., 11 (6), 363-364
  8. Ose L (1996)
    Simvastatin-fluvastatin comparative study - Continued - Reply
    Clin. Drug Invest., 12 (1), 57
  9. Retterstøl K, Stugaard M, Gørbitz C, Ose L (1996)
    Results of intensive long-term treatment of familial hypercholesterolemia
    Am J Cardiol, 78 (12), 1369-74
    DOI 10.1016/s0002-9149(96)00649-2, PubMed 8970408
  10. Sundvold H, Solberg K, Tonstad S, Rødningen OK, Ose L, Berg K, Leren TP (1996)
    A common missense mutation (C210G) in the LDL receptor gene among Norwegian familial hypercholesterolemia subjects
    Hum Mutat, 7 (1), 70-1
    DOI 10.1002/(SICI)1098-1004(1996)7:1<70::AID-HUMU12>3.0.CO;2-P, PubMed 8664907
  11. Tonstad S (1996)
    Familial hypercholesterolaemia: a pilot study of parents' and children's concerns
    Acta Paediatr, 85 (11), 1307-13
    DOI 10.1111/j.1651-2227.1996.tb13916.x, PubMed 8955457
  12. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bønaa KH (1996)
    Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects
    Arterioscler Thromb Vasc Biol, 16 (8), 984-91
    DOI 10.1161/01.atv.16.8.984, PubMed 8696963
  13. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L (1996)
    Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia
    J Pediatr, 129 (1), 42-9
    DOI 10.1016/s0022-3476(96)70188-9, PubMed 8757561
  14. Tonstad S, Ose L (1996)
    Colestipol tablets in adolescents with familial hypercholesterolaemia
    Acta Paediatr, 85 (9), 1080-2
    DOI 10.1111/j.1651-2227.1996.tb14221.x, PubMed 8888922
  15. Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland PM (1996)
    Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives
    Pediatr Res, 40 (1), 47-52
    DOI 10.1203/00006450-199607000-00009, PubMed 8798245
  16. Tonstad S, Sivertsen M, Aksnes L, Ose L (1996)
    Low dose colestipol in adolescents with familial hypercholesterolaemia
    Arch Dis Child, 74 (2), 157-60
    DOI 10.1136/adc.74.2.157, PubMed 8660081
  17. Tonstad S, Sundt E, Ose L, Hagve TA, Fruchart JC, Bard JM, Edén S (1996)
    The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia
    Metabolism, 45 (11), 1415-21
    DOI 10.1016/s0026-0495(96)90124-9, PubMed 8931648

Publications 1995

  1. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, Duriez P (1995)
    Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
    Metabolism, 44 (11), 1447-54
    DOI 10.1016/0026-0495(95)90145-0, PubMed 7476333
  2. BARD JM, OSE L, HAGEN E, DURIEZ P, PFISTER P, FRUCHART JC, DALLONGEVILLE J (1995)
    CHANGES IN PLASMA APOLIPOPROTEIN B-CONTAINING LIPOPARTICLE LEVELS FOLLOWING THERAPY WITH FLUVASTATIN AND CHOLESTYRAMINE
    Am. J. Cardiol., 76 (2), A65-A70
  3. Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J (1995)
    Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group
    Am J Cardiol, 76 (2), 65A-70A
    DOI 10.1016/s0002-9149(05)80021-9, PubMed 7604802
  4. Gørbitz C, Bergei CS, Sivertsen M, Ose L, Abyholm T (1995)
    [Diet and lipid status in pregnant women]
    Tidsskr Nor Laegeforen, 115 (11), 1358-60
    PubMed 7770831
  5. Leren TP, Rødningen OK, Tonstad S, Røsby O, Urdal P, Ose L (1995)
    Identification of the apo B-3500 mutation in the Norwegian population
    Scand J Clin Lab Invest, 55 (3), 217-21
    DOI 10.3109/00365519509089616, PubMed 7638555
  6. Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L (1995)
    Two novel point mutations in the EGF precursor homology domain of the LDL receptor gene causing familial hypercholesterolemia
    Hum Genet, 96 (2), 241-2
    DOI 10.1007/bf00207391, PubMed 7635482
  7. Leren TP, Sundvold H, Rødningen OK, Tonstad S, Solberg K, Ose L, Berg K (1995)
    Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia
    Hum Genet, 95 (6), 671-6
    DOI 10.1007/bf00209485, PubMed 7789953
  8. Løhne K, Urdal P, Leren TP, Tonstad S, Ose L (1995)
    Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells
    Cytometry, 20 (4), 290-5
    DOI 10.1002/cyto.990200404, PubMed 7587716
  9. Nenseter MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S (1995)
    No effect of beta-carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, postmenopausal women
    Scand J Clin Lab Invest, 55 (6), 477-85
    DOI 10.3109/00365519509075385, PubMed 8571077
  10. NORDESTGAARD BG, JAUHIAINEN M, WIKLUND O, FAGER G, STENDER S, DREVON CA, OSE L (1995)
    FIRST ANNUAL COPENHAGEN ATHEROSCLEROSIS CONFERENCE
    Arterioscl. Thromb. Vasc. Biol., 15 (10), 1787-1790
  11. Ose L (1995)
    [Treatment of hyperlipidemia. Guidelines for treatment of hyperlipidemia for secondary prevention of ischemic heart disease]
    Tidsskr Nor Laegeforen, 115 (29), 3629-31
    PubMed 8539720
  12. Ose L, Scott R (1995)
    Erratum to Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia
    Clin Drug Investig, 10 (6), 343
    DOI 10.1007/BF03259374, PubMed 27519335
  13. Ose L, Scott R, Grossman L (1995)
    Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
    Clin Drug Investig, 10 (3), 127-38
    DOI 10.2165/00044011-199510030-00001, PubMed 27519196
  14. Ose L, Søvik O, Vesterhus P, Wefring KW, Aagenaes O (1995)
    [Familial hypercholesterolemia in children. A management program. Procedures for diagnosis and treatment in our pediatric departments]
    Tidsskr Nor Laegeforen, 115 (28), 3514
    PubMed 7491607
  15. Ose L, Tonstad S (1995)
    The detection and management of dyslipidaemia in children and adolescents
    Acta Paediatr, 84 (11), 1213-5
    PubMed 8580613
  16. Ose L, Tonstad S, Vesterhus P, Wefring KW (1995)
    [Diagnosis and treatment of familial hypercholesterolemia in children and adolescents]
    Tidsskr Nor Laegeforen, 115 (28), 3499-503
    PubMed 7491603
  17. Ose L, Aass B, Christophersen B (1995)
    [A rapid analysis of the lipid profile. A comparative study of different analytical methods for determination of blood lipids]
    Tidsskr Nor Laegeforen, 115 (28), 3487-9
    PubMed 7491599
  18. Samdal F, Birkeland KI, Ose L, Amland PF (1995)
    Effect of large-volume liposuction on sex hormones and glucose- and lipid metabolism in females
    Aesthetic Plast Surg, 19 (2), 131-5
    DOI 10.1007/bf00450248, PubMed 7598023
  19. Seedorf U, Wiebusch H, Muntoni S, Christensen NC, Skovby F, Nickel V, Roskos M, Funke H, Ose L, Assmann G (1995)
    A novel variant of lysosomal acid lipase (Leu336-->Pro) associated with acid lipase deficiency and cholesterol ester storage disease
    Arterioscler Thromb Vasc Biol, 15 (6), 773-8
    DOI 10.1161/01.atv.15.6.773, PubMed 7773732
  20. Tonstad S (1995)
    [Antioxidants and cardiovascular disorders--epidemiologic aspects. Should high risk patients receive supplementation?]
    Tidsskr Nor Laegeforen, 115 (2), 227-9
    PubMed 7855818
  21. TONSTAD S, BING RF, FROHLICH J, KARPOV Y, OSE L, ROMICS L, STURMER W, PAWSEY SD, ZHANG IX (1995)
    EFFECTIVENESS OF COLESTIPOL TABLETS VS GRANULES IN PATIENTS WITH MODERATE TO SEVERE HYPERCHOLESTEROLEMIA
    Clin. Drug Invest., 10 (5), 257-263
  22. TONSTAD S, DELANGE P, SIVERTSEN M, OSE L (1995)
    PHYSICAL-FITNESS AND FIBRINOGEN LEVELS AMONG HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN
    Nutr. Metab. Carbiovasc. Dis., 5 (2), 93-97
  23. Tonstad S, Holdaas H, Gørbitz C, Ose L (1995)
    Is dietary intervention effective in post-transplant hyperlipidaemia?
    Nephrol Dial Transplant, 10 (1), 82-5
    PubMed 7724035
  24. Tonstad S, Leren TP, Sivertsen M, Ose L (1995)
    Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway
    Arterioscler Thromb Vasc Biol, 15 (8), 1009-14
    DOI 10.1161/01.atv.15.8.1009, PubMed 7627689
  25. Tonstad S, Ose L, Gørbitz C, Djøseland O, Bard JM, Fruchart JC (1995)
    Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women
    J Intern Med, 238 (1), 39-47
    DOI 10.1111/j.1365-2796.1995.tb00897.x, PubMed 7608645
  26. Tonstad S, Vollebaek LE, Ose L (1995)
    Screening for familial hypercholesterolaemia in relatives
    Lancet, 346 (8987), 1438
    DOI 10.1016/s0140-6736(95)92461-2, PubMed 7475864

Publications 1994

  1. Gørbitz C, Ose L (1994)
    [Iron status in postmenopausal women]
    Tidsskr Nor Laegeforen, 114 (4), 436-8
    PubMed 8009479
  2. Gørbitz C, Ose L (1994)
    [Diet therapy of hypercholesterolemia. Can the diet of persons who already follow a cholesterol-lowering diet be further improved by guidelines given by a clinical nutritionist?]
    Tidsskr Nor Laegeforen, 114 (18), 2106-8
    PubMed 7992266
  3. Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, Bard JM, Fruchart JC, Borge M, Wolf MC (1994)
    Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
    Eur J Clin Pharmacol, 46 (5), 445-9
    DOI 10.1007/bf00191909, PubMed 7957541
  4. Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L (1994)
    Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects
    Atherosclerosis, 111 (2), 175-82
    DOI 10.1016/0021-9150(94)90091-4, PubMed 7718019
  5. Nenseter MS, Volden V, Tonstad S, Gudmundsen O, Ose L, Drevon CA (1994)
    Modification of low density lipoprotein in relation to intake of fatty acids and antioxidants
    World Rev Nutr Diet, 75, 144-8
    DOI 10.1159/000423570, PubMed 7871817
  6. Solberg K, Rødningen OK, Tonstad S, Ose L, Leren TP (1994)
    Familial hypercholesterolaemia caused by a non-sense mutation in codon 329 of the LDL receptor gene
    Scand J Clin Lab Invest, 54 (8), 605-9
    DOI 10.3109/00365519409087539, PubMed 7709162
  7. Tonstad S, Gørbitz C, Ose L, Malt UF (1994)
    [A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia]
    Tidsskr Nor Laegeforen, 114 (19), 2262-4
    PubMed 7992293
  8. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E (1994)
    The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
    Eur J Clin Pharmacol, 46 (5), 405-10
    DOI 10.1007/bf00191901, PubMed 7957533
  9. TONSTAD S, SIVERTSEN M, LEREN TP, ROSBY O, OSE L (1994)
    RESPONSIVENESS TO DIETARY INDULGENCE AMONG PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
    Nutr. Metab. Carbiovasc. Dis., 4 (3), 159-162

Publications 1993

  1. FERDER LF, BERTOLAMI MC, GIANNINI SD, CORTAZAR J, OBONARELLANO A, AGNER E, LETH A, MATTILA S, TIKKANEN MJ, FRUCHART JC, DUTZ W, GUNTHER KH, GUTSCHKER A, HEINEMAN G, MORICKE KR, REUTER W, STEINHAGENTHIESSEN E, KRANKENHAUS MB, TOUTOUZAS P, TAI YT, RUBENSTEIN A, RULL J, OSE L, GARMENDIA F, CARRAGETA MO et al. (1993)
    A MULTICENTER COMPARATIVE TRIAL OF LOVASTATIN AND PRAVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
    Am. J. Cardiol., 71 (10), 810-815
  2. Hagve TA, Furuset T, Christophersen B, Ose L (1993)
    [Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III]
    Tidsskr Nor Laegeforen, 113 (7), 853-6
    PubMed 8480294
  3. Leren TP, Solberg K, Rødningen OK, Ose L, Tonstad S, Berg K (1993)
    Evaluation of running conditions for SSCP analysis: application of SSCP for detection of point mutations in the LDL receptor gene
    PCR Methods Appl, 3 (3), 159-62
    DOI 10.1101/gr.3.3.159, PubMed 8118396
  4. Leren TP, Solberg K, Rødningen OK, Røsby O, Tonstad S, Ose L, Berg K (1993)
    Screening for point mutations in exon 10 of the low density lipoprotein receptor gene by analysis of single-strand conformation polymorphisms: detection of a nonsense mutation-FH469-->Stop
    Hum Genet, 92 (1), 6-10
    DOI 10.1007/bf00216137, PubMed 8103503
  5. Rødningen OK, Leren TP, Røsby O, Tonstad S, Ose L, Berg K (1993)
    Haplotype analysis at the low density lipoprotein receptor locus in normal and familial hypercholesterolemia Norwegian subjects
    Clin Genet, 44 (4), 214-20
    DOI 10.1111/j.1399-0004.1993.tb03883.x, PubMed 7903228
  6. SOLBERG K, RODNINGEN OK, TONSTAD S, OSE L, BERG K, LEREN TP (1993)
    MSPL RFLP IN EXON 18 OF THE LDL RECEPTOR GENE DETECTABLE BY PCR
    Clin. Genet., 44 (2), 111
  7. Solberg K, Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP (1993)
    Short report on DNA marker at candidate locus
    Clin Genet, 44 (2), 111
    PubMed 8275559
  8. Tonstad S, Ose L, Gørbitz C, Harrison EM, de Koning Gans HJ (1993)
    Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe primary hypercholesterolaemia
    Scand J Clin Lab Invest, 53 (5), 457-63
    DOI 10.1080/00365519309092540, PubMed 8210967

Publications 1992

  1. Grønn M, Christensen E, Hagve TA, Christophersen BO (1992)
    Effects of dietary purified eicosapentaenoic acid (20:5 (n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells
    Biochim Biophys Acta, 1125 (1), 35-43
    DOI 10.1016/0005-2760(92)90152-l, PubMed 1533162
  2. Leren TP, Solberg K, Røsby O, Rødningen OK, Tonstad S, Ose L, Berg K (1992)
    A new polymorphism in exon 11 of the LDL receptor gene in healthy people and in familial hypercholesterolemia subjects
    Clin Genet, 42 (5), 224-8
    DOI 10.1111/j.1399-0004.1992.tb03245.x, PubMed 1486698
  3. Ose L (1992)
    [Lovastatin in primary hypercholesterolemia. A Norwegian multicenter study]
    Tidsskr Nor Laegeforen, 112 (29), 3665-9
    PubMed 1471127
  4. Ose L (1992)
    [Triglycerides, HDL and coronary disease. Consensus conference: National Institutes of Health 1992]
    Tidsskr Nor Laegeforen, 112 (21), 2768-71
    PubMed 1412312
  5. Pettersen AG, Eide G, Skjerdal A, Wold I, Ose L (1992)
    [Quality assurance in clinical trials. Problems related to patient information]
    Tidsskr Nor Laegeforen, 112 (25), 3204-7
    PubMed 1462295
  6. Purvis K, Tollefsrud A, Rui H, Haug E, Norseth J, Viksmoen L, Ose L, Lund H (1992)
    Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia
    Eur J Clin Pharmacol, 42 (1), 61-4
    DOI 10.1007/bf00314921, PubMed 1541317
  7. Rødningen OK, Røsby O, Tonstad S, Ose L, Berg K, Leren TP (1992)
    A 9.6 kilobase deletion in the low density lipoprotein receptor gene in Norwegian familial hypercholesterolemia subjects
    Clin Genet, 42 (6), 288-95
    DOI 10.1111/j.1399-0004.1992.tb03258.x, PubMed 1362925
  8. Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR (1992)
    Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo
    Eur J Clin Invest, 22 (4), 229-34
    DOI 10.1111/j.1365-2362.1992.tb01456.x, PubMed 1499639
  9. Stugaard M, Wiig I, Lund H, Ose L, Norseth J (1992)
    [Familial hypercholesterolemia--intensive diet therapy combined with drug therapy]
    Tidsskr Nor Laegeforen, 112 (20), 2642-6
    PubMed 1412289

Publications 1991

  1. Graff-Iversen S, Holm HA, Istad H, Ose L, Rom AK, Kristiansen IS, Thelle D, Torsvik H, Urdal P, Wiik J (1991)
    [Treatment of hypercholesterolemia in adults. A treatment program 1991]
    Tidsskr Nor Laegeforen, 111 (28), 3407-11
    PubMed 1792668
  2. Grønn M, Gørbitz C, Christensen E, Levorsen A, Ose L, Hagve TA, Christophersen BO (1991)
    Dietary n-6 fatty acids inhibit the incorporation of dietary n-3 fatty acids in thrombocyte and serum phospholipids in humans: a controlled dietetic study
    Scand J Clin Lab Invest, 51 (3), 255-63
    DOI 10.3109/00365519109091612, PubMed 1909049
  3. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L (1991)
    Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
    Arterioscler Thromb, 11 (1), 138-45
    DOI 10.1161/01.atv.11.1.138, PubMed 1987991
  4. Tonstad S (1991)
    [Dietary supplementation in the treatment of hyperlipidemia]
    Tidsskr Nor Laegeforen, 111 (28), 3398-400
    PubMed 1665257

Publications 1990

  1. Strømme P, Ose L (1990)
    [Identification of syndromes using a combined computer and video program]
    Tidsskr Nor Laegeforen, 110 (9), 1085-7
    PubMed 2184540
  2. Aakhus T, Brosstad F, Halse J, Ose L, Brodwall EK, Finne P, Natvig J, Stavem P, Heiberg A, Orstavik LA (1990)
    [Are prosecuted parents allowed the benefit of the doubt in cases of child abuse?]
    Tidsskr Nor Laegeforen, 110 (5), 627-8
    PubMed 2309218

Publications 1989

  1. Ose L (1989)
    [Marketing of Carduran]
    Tidsskr Nor Laegeforen, 109 (17-18), 1920-1
    PubMed 2526393
  2. Ose L, Blomhoff JP, Torsvik H (1989)
    [Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]
    Tidsskr Nor Laegeforen, 109 (7-8), 850-2
    PubMed 2705170
  3. Ose L, Tolleshaug H (1989)
    Familial hypercholesterolemia. 50 years of research
    Arteriosclerosis, 9 (1 Suppl), I1-2
    PubMed 2643426

Publications 1988

  1. Everts ME, Retterstøl K, Clausen T (1988)
    Effects of adrenaline on excitation-induced stimulation of the sodium-potassium pump in rat skeletal muscle
    Acta Physiol Scand, 134 (2), 189-98
    DOI 10.1111/j.1748-1716.1988.tb08479.x, PubMed 2852445
  2. Silberg IE, Ose L, Flage T, Nakstad P (1988)
    [Fraser's syndrome--cryptophthalmia]
    Tidsskr Nor Laegeforen, 108 (25), 1998-9
    PubMed 3144053
  3. Smevik B, Enger EA, Ose L (1988)
    Computed tomography of a tuberculous paravertebral abscess
    Z Kinderchir, 43 (6), 430-2
    DOI 10.1055/s-2008-1044106, PubMed 3239258

Publications 1987

  1. Ose L (1987)
    [Treatment of familial hypercholesterolemia]
    Tidsskr Nor Laegeforen, 107 (32), 2836-8, 2840
    PubMed 3321550
  2. Ose L (1987)
    [Cardiovascular diseases: we start with children]
    Nord Med, 102 (10), 265-6
    PubMed 3697042

Publications 1983

  1. Aarskog D, Ose L, Pande H, Eide N (1983)
    Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes
    Am J Med Genet, 15 (1), 29-38
    DOI 10.1002/ajmg.1320150104, PubMed 6407320

Publications 1981

  1. Berg T, Ose T, Ose L, Tolleshaug H (1981)
    Intracellular degradation of 125I-labelled asialo-glycoproteins in rat hepatocytes: effect of leupeptin on subcellular distribution of asialo-fetuin
    Int J Biochem, 13 (3), 253-9
    DOI 10.1016/0020-711x(81)90076-8, PubMed 6163669
  2. Ose L, Røken I, Norum KR, Drevon CA, Berg T (1981)
    The binding of high density lipoproteins to isolated rat hepatocytes
    Scand J Clin Lab Invest, 41 (1), 63-73
    DOI 10.3109/00365518109092016, PubMed 7256194
  3. Wandel M, Norum KR, Berg T, Ose L (1981)
    Binding, uptake, and degradation of 125I-labelled high-density lipoproteins in isolated non-parenchymal rat liver cells
    Scand J Gastroenterol, 16 (1), 71-80
    PubMed 7233082

Publications 1980

  1. Ose L, Ose T, Norum KR, Berg T (1980)
    The intracellular distribution of high density lipoproteins taken up by isolated rat hepatocytes
    Biochim Biophys Acta, 620 (1), 120-32
    DOI 10.1016/0005-2760(80)90191-5, PubMed 6251895
  2. Ose L, Ose T, Reinertsen R, Berg T (1980)
    Fluid endocytosis in isolated rat parenchymal and non-parenchymal liver cells
    Exp Cell Res, 126 (1), 109-19
    DOI 10.1016/0014-4827(80)90475-9, PubMed 7188905
  3. Ose L, Røken I, Norum KR, Berg T (1980)
    The effect of ammonia, chloroquine, leupeptin, colchicine and cytochalasin B on degradation of high density lipoproteins in isolated rat hepatocytes
    Exp Cell Res, 130 (1), 127-35
    DOI 10.1016/0014-4827(80)90049-x, PubMed 7192635
  4. Ose T, Berg T, Norum KR, Ose L (1980)
    Catabolism of (125-I)low density lipoproteins in isolated rat liver cells
    Biochem Biophys Res Commun, 97 (1), 192-9
    DOI 10.1016/s0006-291x(80)80153-7, PubMed 7458932

Publications 1979

  1. Ose L, Ose T, Norum KR, Berg T (1979)
    Uptake and degradation of 125I-labelled high density lipoproteins in rat liver cells in vivo and in vitro
    Biochim Biophys Acta, 574 (3), 521-36
    DOI 10.1016/0005-2760(79)90248-0, PubMed 226159

Publications 1977

  1. Levin LS, Perrin JC, Ose L, Dorst JP, Miller JD, McKusick VA (1977)
    A heritable syndrome of craniosynostosis, short thin hair, dental abnormalities, and short limbs: cranioectodermal dysplasia
    J Pediatr, 90 (1), 55-61
    DOI 10.1016/s0022-3476(77)80764-6, PubMed 830894
  2. Neill CA, Ose L, Kwiterovich PO (1977)
    Hyperlipidemia: clinical clues in the first two decades of life
    Johns Hopkins Med J, 140 (4), 171-6
    PubMed 850334
  3. Ose L (1977)
    [Hyperlipemia in children]
    Tidsskr Nor Laegeforen, 97 (2), 67-73
    PubMed 835105
  4. Ose L, McKusick VA (1977)
    Prophylactiv use of propranolol in the Marfan syndrome to prevent aortic dissection
    Birth Defects Orig Artic Ser, 13 (3C), 163-9
    PubMed 19114

Publications 1976

  1. Helle KB, Serck-Hanssen G, Sövik O, Gutteberg TJ, Hansen JR, Ose L, Stöa KF (1976)
    Circulating dopamine-beta-hydroxylase (DbetaH) and catecholamines in a paediatric phaeochromocytoma
    Clin Exp Pharmacol Physiol, 3 (5), 487-91
    DOI 10.1111/j.1440-1681.1976.tb00627.x, PubMed 975634
  2. Ose L, Fluge G (1976)
    Letter: Usefulness of the xylose test for coeliac disease
    Arch Dis Child, 51 (5), 400-1
    DOI 10.1136/adc.51.5.400, PubMed 938086
  3. Ose L, Kalager T, Grundt IK (1976)
    Serum beta-lipoprotein subfractions in polyacrylamide gel electrophoresis associated with coronary heart disease
    Scand J Clin Lab Invest, 36 (1), 75-9
    DOI 10.1080/00365517609068021, PubMed 176718
  4. Ragnhildstveit E, Ose L (1976)
    Neonatal osteomyelitis caused by group B streptococci
    Scand J Infect Dis, 8 (3), 219-21
    DOI 10.3109/inf.1976.8.issue-3.20, PubMed 788147

Publications 1975

  1. Forsdahl A, Salmi H, Forsdahl F, Ose L, Grundt I (1975)
    [Finnish families in the town of Sør-Varanger. II. A study of blood pressure, height, weight, cholesterol, triglycerides and lipoprotein electrophoresis among Finnish men - combined effects of a change in diet]
    Sykepleien, 62 (16), 728-35
    PubMed 1043245
  2. Ose L (1975)
    Letter: L.D.L. and total cholesterol in cord-blood screening for familial hypercholesterolaemia
    Lancet, 2 (7935), 615-6
    DOI 10.1016/s0140-6736(75)90216-0, PubMed 51449
  3. Ose L (1975)
    [Encephalitis associated with mycoplasma pneumoniae infection in children]
    Tidsskr Nor Laegeforen, 95 (12), 756-8,779
    PubMed 1145545
  4. Ose L, Iden A, Bakke T, Aarskog D (1975)
    Neonatal screening for hyperlipidaemia
    Postgrad Med J, 51 (8), 88-92
    PubMed 1221382
  5. Ose L, Iden A, Bakke T, Aarskog D (1975)
    Neonatal screening for hyperlipidaemia
    Postgrad Med J, 51 (8), suppl 88-92
    PubMed 215987

Publications 1974

  1. Forsdahl A, Salmi H, Forsdahl F, Ose L, Grundt I (1974)
    [Finnish descendants in the municipality of Sor-Varanger--II. An investigation of blood pressure, height, weight, cholesterol, triglycerides and lipoproteins among Finnish descendant men--and the effect of a diet change]
    Tidsskr Nor Laegeforen, 94 (26), 1565-72
    PubMed 4422489
  2. Ose L (1974)
    [Routine methods for fibrinogen determination]
    Tidsskr Nor Laegeforen, 94 (30), 2085-7
    PubMed 4214421
  3. Ose L, Fluge G (1974)
    [The D-xylose-tolerance test as screeningtest for malabsorption diseases in children]
    Tidsskr Nor Laegeforen, 94 (18), 1192-5
    PubMed 4839995

Publications 1973

  1. Ose L (1973)
    [D-xylose tolerance in malabsorption. Method of determination of D-xylose in serum and urine]
    Tidsskr Nor Laegeforen, 93 (28), 2103-5
    PubMed 4773981
 
Page visits: 5534